Search clinical trials for: efanesoctocog alfa (BIVV001)

Total 3070 results

Protalix
Chiesi Farmaceutici S.p.A.

Completed

Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function (BALANCE)

Fabry Disease

United States, Netherlands, Hungary, United Kingdom, Czechia, Norway, Slovenia, Spain, Finland, France, Italy, Switzerland
Yale University
American Heart Association

Completed

Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction

Myocardial Infarction

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I, Stage II, or Stage III Breast Cancer

Breast Cancer | Fatigue | Anemia
Eli Lilly and Company

Completed

The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis

Sepsis

United States, Canada, Brazil, Mexico, Australia, Czech Republic, Slovakia, Spain, Austria, Belgium, Chile, Denmark, Egypt, Finland, France, Germany, India, Italy, Lebanon, Netherlands, New Zealand, Norway, Romania, Russian Federation, Saudi... and more
Ortho Pharmaceuticals

Completed

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy

HIV Infections | Cytopenias

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer

Head and Neck Cancer | Anemia

United States, Canada, Korea, Republic of
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Clinical Affairs, L.L.C.

Terminated

The Safety and Effectiveness of PROCRIT (Epoetin Alfa) in Patients Undergoing Elective Major Abdominal and/or Pelvic Surgery

Hemostasis, Surgical
Biocad

Completed

Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers

Reticulocyte Count
Sanofi
Pulse Infoframe Ltd.

Recruiting

A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)

Niemann-Pick Diseases | Acid Sphingomyelinase Deficiency

United States
Fondation Ophtalmologique Adolphe de Rothschild

Recruiting

Efficacy of Pulmozyme® on Arterial Recanalization in Post-thrombectomy Patients Managed for Ischemic Stroke (NETs-target) (NETs-target)

Ischemic Stroke

France
JCR Pharmaceuticals Co., Ltd.

Active, not recruiting

An Extension Study of JR-171-101 Study in Patients With MPS I

Mucopolysaccharidosis I

United States, Brazil, Japan
Genzyme, a Sanofi Company

Completed

Avalglucosidase Alfa Extension Study (NEO-EXT)

Glycogen Storage Disease Type II Pompe Disease

United States, Belgium, Denmark, France, Germany, Netherlands, United Kingdom
Chiesi Farmaceutici S.p.A.

Active, not recruiting

Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease

Fabry Disease

United States, Netherlands, Australia, Hungary, United Kingdom, Canada, Czechia, Finland, France, Italy, Norway, Slovenia, Spain
Genentech, Inc.

Terminated

A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)

Cystic Fibrosis

United States
Genentech, Inc.

Completed

A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic Fibrosis

Cystic Fibrosis

United States
Genzyme, a Sanofi Company

Completed

Late-Onset Treatment Study Extension Protocol

Glycogen Storage Disease Type II (GSD-II) | Pompe Disease (Late-Onset) | Glycogenesis Type II | Acid Maltase Deficiency (AMD)

United States, France, Canada, Netherlands, Australia
Region Stockholm

Not yet recruiting

The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy (FOXTROT)

Diabetes Complications | Diabetes; Nephropathy (Manifestation)

Sweden
Bayer

Completed

Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934 (DIALOGUE5)

Renal Insufficiency, Chronic | Anemia

United States, Japan
Gilead Sciences

Completed

Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)

Chronic Hepatitis Delta

France, Moldova, Republic of, Romania, Russian Federation
Columbia University
Merck Sharp & Dohme LLC

Withdrawn

Boceprevir in End Stage Renal Disease (ESRD)

End Stage Renal Disease | Hepatitis C Infection
Boston Children's Hospital
Brigham and Women's Hospital; South Shore Hospital

Recruiting

Pulmozyme to Improve COVID-19 ARDS Outcomes

COVID

United States
Genzyme, a Sanofi Company

Completed

Pompe Lactation Sub-Registry

Glycogen Storage Disease | Pompe Disease

United States
Alexion Pharmaceuticals, Inc.
Xcenda, LLC

Active, not recruiting

Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa)

Hypophosphatasia

United States
Swedish Orphan Biovitrum
Cerner Enviza

Active, not recruiting

An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B (B-MORE)

Hemophilia B

Czechia, Greece, Ireland, Italy, Norway, Saudi Arabia, Spain, Sweden, United Kingdom
Swedish Orphan Biovitrum
Cerner Enviza

Completed

A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France (B-SURE)

Haemophilia B

France
AIO-Studien-gGmbH
Merck Serono GmbH, Germany

Terminated

Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer (NEOBIL)

Cholangiocarcinoma | Biliary Tract Cancer

Germany
National Cancer Institute (NCI)

Terminated

A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma

Urothelial Cancer

United States
AryoGen Pharmed Co.

Completed

Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency

Factor VII Deficiency

Iran, Islamic Republic of
PharmaEssentia Japan K.K.
PharmaEssentia

Completed

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics Study of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects

Healthy Volunteers

Australia
Genentech, Inc.

Terminated

A Study of Pulmozyme® (Dornase Alpha) in 3- to 5-Year-Old Patients With Cystic Fibrosis

Cystic Fibrosis
Genzyme, a Sanofi Company

Terminated

A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease

Pompe Disease

United States
University of Colorado, Denver
Genentech, Inc.

Completed

Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme®)

Otitis Media

United States
Novo Nordisk A/S

Completed

Safety, Tolerability and Pharmacokinetics of NN1731 in Healthy Volunteers

Healthy | Congenital Bleeding Disorder

Japan
National Institute of Neurological Disorders and...

Completed

An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease

Fabry Disease

United States
National Institute of Neurological Disorders and...

Completed

Replagal Enzyme Replacement Therapy for Adults With Fabry Disease

Fabry Disease

United States
Hallym University Medical Center

Recruiting

High Dose IV Iron Plus ESA in Chemotherapy-induced Anemia

Anemia

Korea, Republic of
Bayer

Completed

Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934 (DIALOGUE4)

Renal Insufficiency, Chronic | Anemia

United States, Japan
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Recruiting

A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)

Von Willebrand Disease (VWD)

United States, Italy, Spain, Netherlands, Turkey, France, Austria, Germany, Russian Federation
Chiesi Farmaceutici S.p.A.

Terminated

Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)

Acute Respiratory Distress Syndrome

United States, Italy, United Kingdom
The Cleveland Clinic
National Cancer Institute (NCI)

Completed

Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma

Multiple Myeloma | Anemia | Plasma Cell Neoplasm

United States
Sandoz

Terminated

Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients

Anemia | Chronic Renal Insufficiency

Austria, Slovakia, Russian Federation, Romania, Poland, Czechia, France, Germany, India, Bulgaria
Amgen

Completed

Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure (CHF) & Anemia

Anemia | Congestive Heart Failure
University of Aarhus
Amgen

Terminated

Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer

Prostatic Neoplasms | Anemia

Denmark
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks

Cancer | Anemia | Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks

Cancer | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

Randomized, Double-blind, Placebo-controlled Study to Assess Fatigue in Patients With ACD Due to RA Receiving PROCRIT

Rheumatoid Arthritis | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or Radiation

Neoplasms | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia

Anemia | Aged | Hemoglobins
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced Anemia

Anemia | Chemotherapy
Janssen-Cilag B.V.

Completed

A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Transfusions, and Quality of Life in Patients With Cancer Receiving Platinum-containing Chemotherapy

Anemia | Neoplasm

Search clinical trials for: efanesoctocog alfa (BIVV001)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations